JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor.

JMJD2A:445 nM, JMJD2B:435 nM, JARID1A:230 nM, JMJD2E:340 nM, JMJD2D:290 nM

In the H358 and A549 mouse xenograft models, JIB-04 inhibits the activity of Jumonji domain-containing histone demethylases, thereby suppressing tumor cell growth.

In lung and prostate cancer cell lines (IC50=10 nM), JIB-04 downregulates proliferation genes and inhibits cell growth.

For cell viability assays, cells are plated at 1500-3000 cells/well in 96 well plates and treated the next day with increasing doses of compound over 4 days and their viability assessed by standard MTS assays using Promega’s Cell Titer or Cell Titer-Glo reagents according to the manufacturer’s protocols. Absorbance at 490 nm and 650 nm or luminescence is measured by a Spectra Max or a FlouroStar Omega plate reader. Data are normalized to the untreated controls (100% viability). Each cell line is tested in 2-5 independent assays, each containing 4-8 replicates. IC50 values are calculated using DIVISA, a high-throughput software, developed in hous, for storing and analyzing drug sensitivity assays. Dose-response curves are plotted using a non-linear regression model and IC50s are determined from the fitted curves. The average IC50 derived from 2-5 independent assays, each containing 4-8 replicates is reported. (Only for Reference)